This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halkes, C.J.M. Articles by Castro Cabezas, M. Search for Related Content PubMed PubMed Citation Articles by Halkes, C.J.M. Articles by Castro Cabezas, M. Related Collections Lipids Risk Factors Other arteriosclerosis Myocardial cardiomyopathy disease Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1526.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Postprandial Increase of Complement Component 3 in Normolipidemic Patients With Coronary Artery Disease

Effects of Expanded-Dose Simvastatin

C.J.M. Halkes; H. van Dijk; P.P.T. de Jaegere; H.W.M. Plokker; Y. van der Helm; D. W. Erkelens; M. Castro Cabezas

From the Department of Vascular Medicine (C.J.M.H., Y.v.d.H., D.W.E., M.C.C.), the Department of Clinical Immunology (H.v.D.), and the Department of Cardiology (P.P.T.d.J.), University Medical Center Utrecht, Utrecht, the Netherlands, and the Department of Cardiology (H.W.M.P.), St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands.

Correspondence to M. Castro Cabezas, MD, PhD, Department of Vascular Medicine, F02.126, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands. E-mail m.castrocabezas{at}azu.nl

Abstract—— Plasma concentrations of the third complement component (C3) predict the risk of myocardial infarction. Because chylomicrons stimulate C3 production by adipocytes in vitro, we investigated plasma C3 changes in vivo after an oral fat load. Thirty-seven subjects (20 normolipidemic patients with coronary artery disease [CAD] and 17 healthy control subjects) underwent an oral fat load (50 g/m²). C3 was measured at baseline and at 2-hour intervals after fat intake for 10 hours. The effects of lipid lowering by simvastatin were evaluated in 16 patients. Fasting plasma C3 was 1.06±0.26 and 0.90±0.12 g/L in CAD patients and control subjects, respectively. Fasting C3 was correlated with several parameters associated with insulin resistance. The best determinant of fasting C3 was waist circumference (adjusted R²=0.48, ß=0.71, P<0.001); the addition of postprandial triglyceridemia to the model improved it (adjusted R²=0.63). Plasma C3 levels at 2, 4, and 6 hours after fat ingestion were significantly higher than fasting levels in patients and control subjects. C3 increased maximally to 1.39±0.33 g/L in patients and to 1.11±0.18 g/L in control subjects (P<0.01 for patients versus control subjects). Total postprandial triglyceridemia was the best determinant of maximal C3 increase (adjusted R²=0.47, ß=0.70; P<0.001). Treatment with simvastatin decreased fasting and postprandial C3 by 6% and 39%, respectively (P<0.05 for both versus no treatment). Postprandial plasma C3 concentrations increase in CAD patients and control subjects. Fasting C3 is associated with waist circumference, but postprandial C3 increment is associated with postprandial lipemia. Fasting and postprandial C3 concentrations decrease after treatment with simvastatin.

Key Words: atherosclerosis • chylomicrons • complement component 3 • apolipoprotein B • simvastatin

This article has been cited by other articles:

				C. M Phillips, L. Goumidi, S. Bertrais, J. F Ferguson, M. R Field, E. D Kelly, G. M Peloso, L A. Cupples, J. Shen, J. M Ordovas, et al. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome Am. J. Clinical Nutrition, December 1, 2009; 90(6): 1665 - 1673. [Abstract] [Full Text] [PDF]

				E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]

				J. P. H. van Wijk, M. C. Cabezas, E. J. P. de Koning, T. J. Rabelink, R. van der Geest, and I. M. Hoepelman In Vivo Evidence of Impaired Peripheral Fatty Acid Trapping in Patients with Human Immunodeficiency Virus-Associated Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3575 - 3582. [Abstract] [Full Text] [PDF]

				J. P.H. van Wijk, E. J.P. de Koning, M. Castro Cabezas, and T. J. Rabelink Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes Diabetes Care, April 1, 2005; 28(4): 844 - 849. [Abstract] [Full Text] [PDF]

				M. Castro Cabezas, C. Verseyden, S. Meijssen, H. Jansen, and D. W. Erkelens Effects of Atorvastatin on the Clearance of Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5972 - 5980. [Abstract] [Full Text] [PDF]

				J. M. Tsutsui, F. Xie, M. Cano, J. Chomas, P. Phillips, S. J. Radio, J. Lof, and T. R. Porter Detection of retained microbubbles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1036 - 1046. [Abstract] [Full Text] [PDF]

				A. J van Oostrom, H. van Dijk, C. Verseyden, A. D Sniderman, K. Cianflone, T. J Rabelink, and M. Castro Cabezas Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3 Am. J. Clinical Nutrition, March 1, 2004; 79(3): 510 - 515. [Abstract] [Full Text] [PDF]

				C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF]

				C.J.M. Halkes, H. van Dijk, C. Verseyden, P.P.Th. de Jaegere, H.W.M Plokker, S. Meijssen, D.W. Erkelens, and M. C. Cabezas Gender Differences in Postprandial Ketone Bodies in Normolipidemic Subjects and in Untreated Patients With Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1875 - 1880. [Abstract] [Full Text] [PDF]

				G. D. Kolovou, D. Ch. Daskalova, S. A. Iraklianou, E. N. Adamopoulou, N. D. Pilatis, G. C. Hatzigeorgiou, and D. V. Cokkinos Postprandial Lipemia in Hypertension J. Am. Coll. Nutr., February 1, 2003; 22(1): 80 - 87. [Abstract] [Full Text] [PDF]

				S. Meijssen, H. van Dijk, C. Verseyden, D.W. Erkelens, and M. C. Cabezas Delayed and Exaggerated Postprandial Complement Component 3 Response in Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 811 - 816. [Abstract] [Full Text] [PDF]

				S. Meijssen, R. J. Derksen, S. Bilecen, D. W. Erkelens, and M. C. Cabezas In Vivo Modulation of Plasma Free Fatty Acids in Patients with Familial Combined Hyperlipidemia Using Lipid-Lowering Medication J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1576 - 1580. [Abstract] [Full Text] [PDF]